As­traZeneca snaps up ra­dio­phar­ma part­ner for $2B up­front

As­traZeneca is bet­ting $2 bil­lion up­front to buy Fu­sion Phar­ma­ceu­ti­cals, join­ing a land grab in the bur­geon­ing ra­dio­phar­ma­ceu­ti­cals space.

The deal, which al­so in­cludes up to $400 mil­lion in con­tin­gent val­ue rights, un­der­scores As­traZeneca’s am­bi­tion of “re­plac­ing tra­di­tion­al reg­i­mens like chemother­a­py and ra­dio­ther­a­py with more tar­get­ed treat­ments” for can­cer, the British drug­mak­er wrote in a state­ment. It first teamed up with Fu­sion more than three years ago to de­vel­op next-gen­er­a­tion al­pha-emit­ting ra­dio­phar­ma­ceu­ti­cals and com­bi­na­tion ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER